<PAGE> 1
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-KSB/A
X Annual Report Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
For the fiscal year ended June 30, 1995
__ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
Commission File No. 0-10005
BIOCHEM INTERNATIONAL INC.
A Delaware Corporation I.R.S. Employer Identification
No. 39-1272816
Address Telephone Number
- ------- ----------------
W238 N1650 Rockwood Drive (414) 542-3100
Waukesha, Wisconsin 53188-1199
Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, $.02 par value.
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes X No ___
Check if disclosure of delinquent filers in response to Item 405 of Regulation
S-B is not contained in this form and no disclosure will be contained, to the
best of the registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-KSB or any
amendment to this Form 10-KSB. X
Revenues for the fiscal year ending June 30, 1995 are $25,055,637
The aggregate market value of the Common Stock of the Company held by
non-affiliates on August 31, 1995 was approximately $7,957,894, computed by
reference to the average ($3.50) of the bid and ask prices of the Common Stock
as reported by the National Quotation Bureau. For purposes of this calculation,
officers and directors of the registrant were considered affiliates of the
registrant.
The number of shares outstanding of the Company's Common Stock, par value $.02
per share, on August 31, 1995 was 13,083,284.
Exhibit Index on Page 36
Page 1 of 47
<PAGE> 2
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
BIOCHEM INTERNATIONAL INC.
Dated: October 31, 1995 By /s/ Ann M. Johnson
--------------------
Ann M. Johnson, Vice
President of Finance
and Operations
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
registrant and in the capacities indicated on the 31st day of October, 1995.
Page 43 of 47
<TABLE> <S> <C>
<ARTICLE> 5
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> YEAR
<FISCAL-YEAR-END> JUN-30-1995
<PERIOD-END> JUN-30-1995
<CASH> 2,628
<SECURITIES> 0
<RECEIVABLES> 3,751
<ALLOWANCES> 0
<INVENTORY> 2,686
<CURRENT-ASSETS> 10,580
<PP&E> 2,259
<DEPRECIATION> 821
<TOTAL-ASSETS> 12,305
<CURRENT-LIABILITIES> 2,191
<BONDS> 0
<COMMON> 262
0
0
<OTHER-SE> 9,851
<TOTAL-LIABILITY-AND-EQUITY> 12,305
<SALES> 25,055
<TOTAL-REVENUES> 25,055
<CGS> 11,310
<TOTAL-COSTS> 11,310
<OTHER-EXPENSES> 7,057
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 105
<INCOME-PRETAX> 6,734
<INCOME-TAX> 2,475
<INCOME-CONTINUING> 4,259
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 4,259
<EPS-PRIMARY> 0.32
<EPS-DILUTED> 0.32
</TABLE>
